Events

Time: 2:00PM - 4:30PM
Location: Lobby

RSVP  LabCentral residents contact Clancy for the free code

Have you heard the headlines? As AOBiome purports, "Bacteria is the new black". Or, as Ron Leuty puts it, "Big Pharma is hungry for bacteria". 

Everyone is talking about the gut, and big pharma is intrigued. Johnson & Johnson Innovation, JLABS is hosting a microbiome-focused panel discussion with microbiome leaders from across big pharma, including one of the first movers in this emerging field, the Janssen Human Microbiome Institute, part of Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. 

Hear from Pfizer, Merck, UCB, and Janssen at this unique meeting of the minds. The representatives will discuss:

• The differences and similarities between the various research facilities cropping up in Cambridge.
• What makes the microbiome exciting to pharma?
• What is attractive to big pharma when it comes to the microbiome?
• What's the best route forward for your company?

Panelists: 
John Delyani | Executive Director, Business Development and Licensing, Merck
Dirk Gevers | Global Head, Janssen Human Microbiome Institute 
Roger Palframan | Head Innovation Super Networks, UCB 
Nilufer Seth | Senior Principal Scientist, Pfizer
Nikola Trbovic | Director, R&D Technology Strategy, Pfizer
[moderator] Bernat Olle | CEO, Vedanta Biosciences

Agenda: 
2:00 PM | Registration Opens, Networking
2:30 PM | Investor Panel Discussion
3:30 PM | Q&A 
4:00 PM | Networking Reception
4:30 PM | Program Close